Coherus Oncology — Third Quarter 2026 Earnings Summary

Coherus Oncology reported third-quarter 2026 net revenue of $14.0 million from LOQTORZI, representing a 25% increase compared to the same period in 2025. The company announced a strategic prioritization plan to focus development efforts on tagmokitug and toripalimab for esophageal cancer while deprioritizing other indications. To align with these forward-focused needs, Coherus reduced its headcount by approximately 30%, a move expected to lower core quarterly cash burn by $6 million to $7 million. The company reported a net loss from continuing operations of $38.9 million for the quarter, with cash and cash equivalents totaling $83.6 million as of September 30, 2026.